Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Eric O'Neill

A. Oligomeric NPM and AKT phosphorylation site pS48. B. Blocking AKT phosphorylation of NPM promotes p14ARF localisation at the nucleolus and reduced p53 levels.

For cancers to develop, cells must acquire mutations and epigenetic alterations that prevent the normal control of proliferation and survival. While there are multiple signalling pathways that could be targeted for mutation, there are key genes that are recurrently altered in tumours. Our research focuses on the most frequent and clinically relevant events to understand how alteration of signalling pathways contributes to disease onset and affects treatment outcomes.

RAS is a family of proteins expressed in all cells. Our work focuses on how oncogenic RAS activation combines with tumour suppressor events such as loss of p53 function to allow tumour growth and invasion. By understanding these common events we aim to better define patient’s cohorts and provide a scientific rationale for personalised medicine approaches. In particular we have been exploring this within a multi-disciplinary team tackling pancreatic cancer.

Our lab has focused on the RAS effector RASSF1, which is significantly inactivated by CpG island methylation in all major solid tumours. Epigenetic silencing of the RASSF1 promoter not only associates with tumour onset but also affects prognosis and is being adopted as a potential predictive biomarker for treatment in certain cancers.

We have concentrated on uncovering the role for RASSFs in normal biology to understand exactly why loss of expression has such widespread association with cancer initiation. Through this approach we have found that RASSF1A plays a key role in governing control of the hippo stem cell pathway and is important for genomic protection via the familial breast cancer tumour suppressor gene, BRCA2.

We are continuing to look at both these aspects with the intention of highlighting intervention strategies that are biologically relevant to patients with RASSF1 methylation, alongside developing plasma based detection methods for this epigenetic event. We are collaborating with projects in lung, breast and colorectal susceptibility where RASSF1A methylation has a poor prognosis and are working together with clinicians and developmental biologists on the role of defective stem cell regulation in the onset of gliomas.

Cell Signalling 2

Figure 2: Loss of RASSF1 expression correlates with loss of the YAP partner and differentiation factor, RUNX2 in colorectal adenocarincomas. Normalised expression levels with red = upregulation and blue = downregulation.

Related research themes